AEHR
Aehr Test Systems
AEHR offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
ASTS
AST SpaceMobile, Inc.
ASTS has the edge over AEHR overall, supported by stronger valuation and stronger fundamentals.
AEHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Under pressure | |
| Strong |
AEHR's revenue and balance sheet are currently strong, and its profitability is stable, but its cash flow is under pressure.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
AEHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $0.69 | -99% |
| Fair | 44x | $2.18 | -96% |
| Expensive | 83x | $4.16 | -93% |
| Current | 1,221x | $61.04 | — |
Historical ranges are pointers, not guarantees.
AEHR's PE is in its expensive range at 1221x.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
AEHR Forward outlook
There aren't enough analyst estimates for AEHR to show an outlook.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
AEHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.05 | +$0.27 |
| Q2 2026 | -$0.23 | -$0.10 |
| Q1 2026 | -$0.38 | -149% |
| Q4 2025 | -$0.30 | -140% |
| Q3 2025 | -$0.22 | -122% |
| Q2 2025 | -$0.13 | -112% |
| Q1 2025 | $0.78 | +50% |
| Q4 2024 | $0.75 | +5.6% |
AEHR has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
AEHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33M | +201% |
| Q2 2026 | $18.8M | +34% |
| Q1 2026 | $10.3M | -44% |
| Q4 2025 | $9.9M | -27% |
| Q3 2025 | $11M | -16% |
| Q2 2025 | $14.1M | -15% |
| Q1 2025 | $18.3M | +142% |
| Q4 2024 | $13.5M | -37% |
AEHR's revenue is growing: $33M last quarter, up 201% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +55 points |
| Q2 2026 | -6.4% | +16 points |
| Q1 2026 | -41% | -35 points |
| Q4 2025 | -47% | -36 points |
| Q3 2025 | -37% | -38 points |
| Q2 2025 | -23% | -38 points |
| Q1 2025 | -6.1% | +21 points |
| Q4 2024 | -11% | -37 points |
AEHR has the edge over ASTS on profitability, with a higher operating margin.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over AEHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
AEHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.1M | -$1.4M |
| Q2 2026 | $1.7M | +$6.8M |
| Q1 2026 | -$3.8M | -$502K |
| Q4 2025 | -$1.6M | +$4.6M |
| Q3 2025 | -$1.7M | -177% |
| Q2 2025 | -$5.1M | -535% |
| Q1 2025 | -$3.3M | -$174K |
| Q4 2024 | -$6.2M | -$5.5M |
AEHR has the edge over ASTS on cash flow, with more consistent year-over-year improvement.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
AEHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.3% | +2.9M shares |
| 1 year | +12% | +3.6M shares |
| 3 years | +15% | +4.3M shares |
AEHR has 34M diluted shares, up 12% from a year ago.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over AEHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
AEHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -16.1x | Net Cash |
| Q4 2024 | -68.8x | Net Cash |
| Q3 2024 | -5.4x | Net Cash |
| Q2 2024 | -4.6x | Net Cash |
| Q1 2024 | -3.5x | Net Cash |
| Q4 2023 | -2.6x | Net Cash |
| Q3 2023 | -2.9x | Net Cash |
| Q2 2023 | -2.2x | Net Cash |
AEHR has more cash than debt.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AEHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 7.9 | Oversold |
AEHR's weekly RSI is 44 (neutral) and its Stochastic is 8 (oversold).
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
AEHR PE vs Technology Sector
| Metric | AEHR | Sector median | Relative |
|---|---|---|---|
| PE | 1,221x | 28x | 4,282% above |
| PE % | 100 | 35 | 65 pts above |
AEHR is trading at 1221x earnings, a 4282% premium to the Technology sector's median of 28x.
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
AEHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.7 | 16% below |
| 20 week MA | $82.8 | 26% below |
| 50 week MA | $66.6 | 8.3% below |
| 100 week MA | $41.3 | 48% above |
| 200 week MA | $32.9 | 85% above |
AEHR has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
AEHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.00 | $2.47 | +24% |
| 2021 | $2.47 | $20.5 | +729% |
| 2022 | $20.5 | $21.0 | +2.5% |
| 2023 | $21.0 | $26.5 | +26% |
| 2024 | $26.5 | $16.5 | -38% |
| 2025 | $16.5 | $21.5 | +30% |
| 2026 YTD | $21.5 | $61.0 | +184% |
AEHR has the edge over ASTS on returns for 2026, with the stronger performance.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.